Abstract Library

#4449 Treatment of MiNEN with peptide receptor radionuclide therapy

Introduction: Mixed non-neuroendocrine and neuroendocrine neoplasms (MiNENs) of gastrointestinal tract are rare tumours with characteristic histological features include at least 30% of both neuroendocrine and non-neuroendocrine components of the whole neoplasm. They are usually treated with surgical resection and chemotherapy in advanced disease. However, there is scarcity of data for the use of peptide receptor radionuclide therapy (PRRT) in these tumours.

Conference:

Presenting Author: Shekhda K

Authors: Shekhda K, Luong T, Paterson A, Navalkissoor S, Krell D,

Keywords: MiNEN, PRRT, DOTATATE,

#3827 Prevalence of Clonal Hematopoiesis (CH) in neuroendocrine tumor (NET) patients prior to Lutetium 177 dotatate therapy (Lu177) and the risk of cytopenia – A prospective study of 37 patients

Introduction: Lu177 has shown efficacy in advanced NET but with significant hematologic toxicity, including therapy-related myeloid neoplasm (t-MN). CH is defined by acquisition of somatic mutations in hematopoietic stem cells with potential for expansion over time.

Conference:

Presenting Author: Sonbol M

Authors: Sonbol M, Kusne Y, Lasho T, Elsabbagh Z, Mangaonkar A,

Keywords: clonal hematopoiesis, neuroendocrine, PRRT, Lu177, t-MN, CHIP,

#384 A Pilot Study on the Immunohistochemical Expression of Chromogranin and/or Synaptophysin in Moderate to Poorly Differentiated Gastroenteropancreatic Carcinomas

Introduction: Recent advances in specific treatment for neuroendocrine tumors (NETs) prompted us to reinvestigate the old phenomenon of neuroendocrine differentiation in carcinomas of the GI tract which has previously been shown to carry no prognostic significance.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Shek T, Lam W, Yao H, Tang V, Mak S,

Keywords: NET, IHC,